Company: Nkarta Therapeutics
Job title: CSO
James Trager joined Nkarta Therapeutics, as Senior Vice President of R&D in 2016 and leads all discovery and development efforts. Nkarta is a South San Francisco based startup focused on the use of Natural Killer cells in the treatment of cancer. James is deeply versed in the development and application of cellular therapies for cancer, with broad exposure from discovery to development, quality control, manufacturing, clinical application and regulatory issues surrounding these complex therapies. He previously served as Vice President of Research and Development at Dendreon, where he was responsible for product development, clinical immunology, and analytical development, supporting the late stage development of sipuleucel-T through clinical study, approval, and commercialization. Prior to Dendreon, James was a Senior Scientist at Geron; he was part of the team that cloned human telomerase, and later established a Quality Control function for the manufacture and clinical development of a telomerase inhibitor.
James is a graduate of St. John’s College in Santa Fe New Mexico; and served as a Peace Corps volunteer in the Central African Republic. He received his doctorate in Molecular Biology and Biochemistry from the University of California at Berkeley, where he performed mechanistic studies on the src oncogene.
Industry Leader’s Fireside Chat 10:00 am
An executive panel discussion from the C-level leaders of the NK space to set the scene on NK cell therapy development. Ask your questions live to understand the expert’s thoughts on key topics including gene engineering, allogeneic drug development, optimal cell sources, driving clinical success in solid tumors and future thoughts on market access and…Read more
day: Day One